Loviride

• CAT Number: M093940
• CAS Number: 147362-57-0
• Molecular Formula: C17H16Cl2N2O2
• Molecular Weight: 351.227
• Purity: ≥95%
• Target: DNA polymerase inhibitor
• Storage: Desiccate at +4C
• IUPAC Name: 2-(2-acetyl-5-methylanilino)-2-(2,6-dichlorophenyl)acetamide
• InChI: InChI=1S/C17H16Cl2N2O2/c1-9-6-7-11(10(2)22)14(8-9)21-16(17(20)23)15-12(18)4-3-5-13(15)19/h3-8,16,21H,1-2H3,(H2,20,23)
• InChIKey: CJPLEFFCVDQQFZ-UHFFFAOYSA-N
• SMILES: CC1=CC(=C(C=C1)C(=O)C)NC(C2=C(C=CC=C2Cl)Cl)C(=O)N

Loviride, also known as R-89439, is a RNA-directed DNA polymerase inhibitor potentially for the treatment of HIV infection.

Reference

1:Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze-dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling. Van Eerdenbrugh B, Froyen L, Martens JA, Blaton N, Augustijns P, Brewster M, Van den Mooter G.Int J Pharm. 2007 Jun 29;338(1-2):198-206. Epub 2007 Feb 9. PMID: 17363200 2:AVANTI 1: randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus loviride in HIV-infected antiretroviral-naive patients. AVANTI Study Group. Gatell J, Lange J, Gartland M.Antivir Ther. 1999;4(2):79-86. PMID: 10682152 3:Quality of life and treatment satisfaction after the addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens in treatment-experienced patients with HIV infection. Chatterton ML, Scott-Lennox J, Wu AW, Scott J.Pharmacoeconomics. 1999;15 Suppl 1:67-74. PMID: 10537443 4:Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride. Miller V, de Béthune MP, Kober A, Stürmer M, Hertogs K, Pauwels R, Stoffels P, Staszewski S.Antimicrob Agents Chemother. 1998 Dec;42(12):3123-9. PMID: 9835502 Free PMC Article5:Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. [No authors listed]Lancet. 1997 May 17;349(9063):1413-21. PMID: 9164314 6:Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients. Staszewski S, Miller V, Rehmet S, Stark T, De Crée J, De Brabander M, Peeters M, Andries K, Moeremans M, De Raeymaeker M, Pearce G, Van den Broeck R, Verbiest W, Stoffels P.AIDS. 1996 May;10(5):F1-7. PMID: 8724034 7:Evaluation of the efficacy and tolerance of R 018893, R 089439 (loviride) and placebo in asymptomatic HIV-1-infected patients. Loviride Collaborative Study Group. Staszewski S, Miller V, Kober A, Colebunders R, Vandercam B, Delescluse J, Clumeck N, Van Wanzeele F, De Brabander M, De Creé J, Moeremans M, Andries K, Boucher C, Stoffels P, Janssen PA.Antivir Ther. 1996 Jan;1(1):42-50. No abstract available. PMID: 11322258